Your browser doesn't support javascript.
loading
Assessment of post-myocardial infarction lipid levels and management: Results from a tertiary care hospital of Pakistan.
Rauf, Rubina; Soomro, Muhammad Ismail; Khan, Muhamman Nauman; Kumar, Mukesh; Soomro, Najia Aslam; Kazmi, Khawar Abbas.
Afiliación
  • Rauf R; Department of Preventive Cardiology, National Institute of Cardiovascular Diseases, Karachi 75510, Pakistan. drrubinarauf@gmail.com.
  • Soomro MI; Department of Preventive Cardiology, National Institute of Cardiovascular Diseases, Karachi 75510, Pakistan.
  • Khan MN; Department of Adult Cardiology, National Institute of Cardiovascular Diseases, Karachi 75510, Pakistan.
  • Kumar M; Department of Adult Cardiology, National Institute of Cardiovascular Diseases, Karachi 75510, Pakistan.
  • Soomro NA; Department of Cardiology, Liaquat National Hospital, Karachi 74800, Pakistan.
  • Kazmi KA; Department of Preventive Cardiology, National Institute of Cardiovascular Diseases, Karachi 75510, Pakistan.
World J Cardiol ; 16(5): 282-292, 2024 May 26.
Article en En | MEDLINE | ID: mdl-38817645
ABSTRACT

BACKGROUND:

Lipid treatment practices and levels in post-acute myocardial infarction (AMI) patients, which are crucial for secondary prevention.

AIM:

To evaluate the lipid treatment practices and lipid levels in post-myocardial infarction (MI) patients at a tertiary care hospital in Pakistan.

METHODS:

In this cross-sectional study, we analyzed patients who had experienced their first AMI event in the past 3 years. We assessed fasting and non-fasting lipid profiles, reviewed statin therapy prescriptions, and examined patient compliance. The recommended dose was defined as rosuvastatin ≥ 20 mg or atorvastatin ≥ 40 mg, with target total cholesterol levels set at < 160 mg/dL and target low-density lipoprotein cholesterol (LDL-C) at < 55 mg/dL.

RESULTS:

Among 195 patients, 71.3% were male, and the mean age was 57.1 ± 10.2 years. The median duration since AMI was 36 (interquartile range 10-48) months and 60% were diagnosed with ST-segment elevation MI. Only 13.8% of patients were advised to undergo lipid profile testing after AMI, 88.7% of patients were on the recommended statin therapy, and 91.8% of patients were compliant with statin therapy. Only 11.5% had LDL-C within the target range and 71.7% had total cholesterol within the target range. Hospital admission in the past 12 months was reported by 14.4%, and the re-admission rate was significantly higher among non-compliant patients (37.5% vs 5.6%). Subsequent AMI event rate was also significantly higher among non-compliant patients (43.8% vs 11.7%).

CONCLUSION:

Our study highlights that while most post-AMI patients received the recommended minimum statin therapy dose, the inadequate practice of lipid assessment may compromise therapy optimization and raise the risk of subsequent events.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: World J Cardiol Año: 2024 Tipo del documento: Article País de afiliación: Pakistán Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: World J Cardiol Año: 2024 Tipo del documento: Article País de afiliación: Pakistán Pais de publicación: Estados Unidos